SYRS - サイロス・ファ―マシュ―ティカルズ (Syros Pharmaceuticals Inc.) サイロス・ファ―マシュ―ティカルズ

 SYRSのチャート


 SYRSの企業情報

symbol SYRS
会社名 Syros Pharmaceuticals Inc (サイロス・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 シロス・ファーマーセウティカルズ(Syros Pharmaceuticals Inc.)はバイオ医薬品会社である。同社はヒト疾病組織における未知のデオキシリボ核酸(DNA)の領域を分析し、ゲノム的に定義された患者集団に関連する標的を同定し、薬物を創出するように設計された遺伝子制御プラットフォームを提供する。同社はがんおよび免疫媒介疾患の治療法の開発に注力し、遺伝子制御薬のパイプラインを構築している。同社の薬物プログラムには、SY-1425(レチノイン酸受容体アルファ(RARa)アゴニスト)およびSY-1365(サイクリン依存性キナーゼ7(CDK7)阻害剤)が含まれる。SY-1425(タミバロチン)は、転写因子RARaの経口の強力で選択的なアゴニストまたは活性化剤である。SY-1365は、CDK7として知られた転写キナーゼの小分子阻害剤である。同社はそのプラットフォームを使用して、追加の癌、炎症性疾患および他の疾患にわたって遺伝子発現プログラムを分析し、患者の特定のサブセットにおける治療的介入の最適点を同定する。   サイロス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。主として、遺伝子の起動や抑制をコントロ―ルするゲノム制御分野に基づき、ガンや免疫性疾患の治療薬の開発、製造を行う。同社の遺伝子制御プラットフォ―ムは、ゲノム的定義に関連した新たな遺伝子制御の特定や遺伝子制御を麻痺させることを目的とする。本社はマサチュ―セッツ州ケンブリッジ。   Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
本社所在地 620 Memorial Drive Suite 300 Cambridge MA 02139 USA
代表者氏名 Peter Wirth ピーター・ワース
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-744-1340
設立年月日 40848
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 56人
url www.syros.com
nasdaq_url https://www.nasdaq.com/symbol/syrs
adr_tso
EBITDA EBITDA(百万ドル) -57.38400
終値(lastsale) 8.26
時価総額(marketcap) 277985253.14
時価総額 時価総額(百万ドル) 239.28270
売上高 売上高(百万ドル) 0.74500
企業価値(EV) 企業価値(EV)(百万ドル) 114.95270
当期純利益 当期純利益(百万ドル) -57.63700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Syros Pharmaceuticals Inc revenues decreased 32% to $745K. Net loss increased 15% to $28.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research_Development - Balancing value increase of 11% to $21M (expense) Stock-based Compensation in SGA increase of 75% to $2.2M (expense).

 SYRSのテクニカル分析


 SYRSのニュース

   Global Blood Therapeutics Consensus Indicates Potential 176.4% Upside  2021/09/29 12:01:29 DirectorsTalk
Global Blood Therapeutics found using ticker (GBT) have now 19 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 138 and 30 with a mean TP of 72.47. With the stocks previous close at 26.22 this indicates there is a potential upside of 176.4%. The 50 day MA is 28.03 and the 200 day MA is 35.13. The company has a market capitalisation of $1,657m. Company Website: /> [stock_market_widget type="chart" symbol="GBT" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Global Blood Therapeutics, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. The company offers Oxbryta tablets, an oral, once-daily therapy for sickle cell disease (SCD). It is evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase 2a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing inclacumab, a novel human monoclonal antibody to treat vaso-occlusive crises; and GBT601, a hemoglobin polymerization inhibitor.
   Syros Reports Inducement Grant to Chief Commercial Officer under Nasdaq Listing Rule 5635(c)(4)  2021/09/28 20:01:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS) ("Syros" or the "Company"), a leader in the development of medicines that control the expression of genes, today announced the grant of an inducement stock option award to Conley Chee, the Company’s recently hired Chief Commercial Officer, in accordance with Mr. Chee’s employment offer letter. The grant was approved by the Company’s Board of Directors and was made as a material inducement to Mr. Chee’s acceptance of employm
   Syros Pharmaceuticals (SYRS) Investor Presentation  2021/09/27 21:00:46 Seeking Alpha
   Syros Announces Appointment of Conley Chee as Chief Commercial Officer  2021/09/27 12:00:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Conley Chee as the companys first Chief Commercial Officer. Mr. Chee brings 20 years of pharmaceutical sales leadership, marketing and strategy experience in the U.S. and globally, with particular expertise in driving commercial strategy for novel medicines for the treatment of cancer. We are pleased to welcom
   Mind-blowing stocks: Worksport Ltd. (NASDAQ:WKSP -7.77%), Syros Pharmaceuticals, Inc. (NASDAQ:SYRS 2.04%)  2021/09/24 00:01:27 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Mind-blowing stocks: Worksport Ltd. (NASDAQ:WKSP -7.77%), Syros Pharmaceuticals, Inc. (NASDAQ:SYRS 2.04%) appeared first on Stocks Equity .
   Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2021 Results - Earnings Call Transcript  2021/08/08 23:44:12 Seeking Alpha
   Syros Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/05 15:33:17 Seeking Alpha
   Syros Pharmaceuticals EPS beats by $0.03, beats on revenue  2021/08/05 11:47:16 Seeking Alpha
   Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2021/08/05 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events. As Syros advances toward becoming a commercial-stage company, we are focused on execution across our growing portfolios in targeted hematology and selective CDK inhibition and made great strides in the secon
   Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021  2021/07/29 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 4156527. A webcast
   Syros Pharmaceuticals, Inc. (SYRS) CEO Nancy Simonian on Q2 2021 Results - Earnings Call Transcript  2021/08/08 23:44:12 Seeking Alpha
   Syros Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/05 15:33:17 Seeking Alpha
   Syros Pharmaceuticals EPS beats by $0.03, beats on revenue  2021/08/05 11:47:16 Seeking Alpha
   Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones  2021/08/05 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended June 30, 2021, and provided an update on recent accomplishments and upcoming events. As Syros advances toward becoming a commercial-stage company, we are focused on execution across our growing portfolios in targeted hematology and selective CDK inhibition and made great strides in the secon
   Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021  2021/07/29 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, August 5, 2021 to report its second quarter 2021 financial results and provide a corporate update. To access the live conference call, please dial 866-595-4538 (domestic) or 636-812-6496 (international), and refer to conference ID 4156527. A webcast

 関連キーワード  (医薬品 米国株 サイロス・ファ―マシュ―ティカルズ SYRS Syros Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)